Chroma Therapeutics Advances Novel Targeted Agent towards Clinical Development; Receives Milestone - Gilde Healthcare

Chroma Therapeutics Advances Novel Targeted Agent towards Clinical Development; Receives Milestone

January 3, 2013

Oxford – Chroma Therapeutics Limited announced today that GlaxoSmithKline (GSK) has approved the progression of Chroma’s novel macrophage-targeted HDAC inhibitor, CHR-5154, towards human clinical development subject to regulatory approval, triggering an undisclosed milestone payment from GSK.

HDAC inhibitors have been demonstrated to have broad anti-inflammatory activity, in addition to their activity in a variety of cancers, and may be useful for the treatment of severe inflammatory disorders such as rheumatoid arthritis. CHR-5154 is an orally-dosed agent utilising Chroma’s proprietary esterasesensitive motif (ESM) technology, which enables compounds to be targeted to specific cells (macrophages) critically involved in the inflammatory disease process. Chroma has already progressed CHR2845 from its ESM technology platform into human clinical trials. Separately, Chroma announced that its collaboration with GSK has been extended to enable their Epinova Discovery Performance Unit to apply Chroma’s ESM technology to a novel GSK epigenetic target. Chroma will receive an upfront cash payment and is eligible to receive milestones and royalties based on compounds arising from this element of the collaboration. 

Richard Bungay, CEO of Chroma, commented:

“We are delighted to be able to achieve this key milestone and progress this highly innovative agent towards clinical development. We will assess its potential to address significant unmet needs in patients with severe inflammatory disorders. Further, the extension of our collaboration with GSK highlights the potential of the ESM platform to deliver a pipeline of differentiated therapeutic agents addressing a range of novel disease targets.”

Gilde Healthcare company Moximed reports treatment of first commercial patients post FDA approval

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced the first commercial cases of the MISHA™ Knee System, an implantable shock absorber...
September 6, 2023

Gilde Healthcare company Withings launches its next-generation scanwatch with enhanced sensors to monitor additional health metrics 24/7

In 2014, Withings, a pioneer of the digital health movement, announced the world’s first hybrid watch. Today it furthers its leadership of the hybrid connected watch sector, unveiling the latest generation of its groundbreaking ScanWatch....
August 31, 2023

Gilde Healthcare company Big Health expands into adolescent mental health through acquisition of Limbix

Big Health, the leading provider of non-drug digital treatments for mental health, has acquired Limbix, creators of the first, evidence-based digital therapeutic for teens and young adults with symptoms of depression. Since its founding in...
July 17, 2023